The present study evaluated the antinociceptive effect of the pro-inflammatory cytokines inhibitor diacerein in mice and its possible mechanism of action. The antinociception produced by diacerein was tested at different sites of action, moreover selective antagonists or agonists were used to identify the mechanism that may be involved in its antinociceptive action against acetic acid-induced visceral pain. Diacerein administered systemically (intraperitoneal [i.p.] or intra-gastric [i.g.] routes), supra-spinally (i.c.v.), spinally (i.t.) or peripherally (in association with the irritant agent) inhibited the visceral nociception induced by acetic acid in mice. Interestingly, diacerein treatment (25 mg/kg, i.p. or 50 mg/kg, i.g.) produced long-lasting (for up to 4 h) inhibition of acetic acid-induced nociception. Intraperitoneal treatment of mice with diacerein (25.0 mg/kg) inhibited somatic nociception induced by i.t. injection of glutamate, NMDA, kainate, and trans-ACPD but not that caused by AMPA. Diacerein (5.0-25.0 mg/kg) also produced dose related inhibition of interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α) induced nociception. These results indicate that diacerein produces antinociception by inhibiting glutamatergic transmission through both ionotropic and metabotropic receptors as well as activity of pro-inflammatory cytokines.
Introduction
Diacerein (4,5-diacetoxy-9,10-dihydro-9,10-dioxo-2 anthracenecarboxylicacid) is a purified anthraquinone that is entirely transformed during absorption into rhein, the active metabolite found in plasma and synovial fluid. It belongs to a new class of anti-osteoarthritis drugs, known as "disease modifying osteoarthritis drugs (DMOAD)" or "chondroprotective agents" (Verbruggen, 2006; Pelletier and Martel-Pelletier, 2007) . For its actions both in vivo and in vitro, diacerein has been used in the treatment of osteoarthritis and demonstrated benefits in alleviating joint pain in humans and in rodent models of the disease (Pavelka et al., 2007; Pelletier et al., 2000; Tamura et al., 1999 Tamura et al., , 2001 Tamura et al., , 2002 ) (for review see, Hunter and Wise, 2007) . Recent data from our group showed that diacerein inhibits neuropathic pain induced by partial ligation of the sciatic nerve and also produced anti-allodynic effects against carrageenan-and complete Freund's adjuvant (CFA)-induced inflammatory nociception (Quintão et al., 2005) .
Although the mechanisms involved on those actions are still incompletely understood, several studies have shown that diacerein and rhein decrease pro-inflammatory cytokines (such as interleukin-1β and tumor necrosis factor alpha [TNF-α] ) release and production either in vitro (Martel-Pelletier et al., 1998; Yaron et al., 1999) or in vivo (Martel-Pelletier et al., 1998; Moldovan et al., 2000) , as well as inhibit in vitro NF-κβ activation (Mendes et al., 2002) . In fact, NF-κβ, a transcription factor that acts as a central mediator of the immune response, is one of the most important regulators of gene expression among the family of pro-inflammatory mediators (Bonizzi and Karin, 2004; Yoshida et al., 1999) . Moreover, diacerein has been found to prevent cartilage breakdown (Moore et al., 1998) and protects against Baker's yeast-induced fever and peritoneal leukocyte migration (Pasin et al., 2010) due to inhibition of the release of pro-inflammatory cytokines.
Although the analgesic effect of diacerein and its action to inhibit the production and release of pro-inflammatory cytokines is well established, there is a lack of a broader perspective of the extent to what mechanisms of action may be applied in well-established models of acute antinociception. Therefore, we designed the present study to analyze the antinociceptive effects of diacerein against acetic Pharmacology, Biochemistry and Behavior 102 (2012) [549] [550] [551] [552] [553] [554] acid-induced visceral pain as well as glutamate agonists-or pro-inflammatory cytokines-induced somatic pain. Here, we shown that diacerein exhibited antinociceptive effect in different sites of action and that this effect may be related to an inhibition of the glutamate-pro-inflammatory cytokines signaling pathway.
Materials and methods

Animals
Experiments were conducted using male Swiss mice (25-35 g), housed at 22 ± 2°C under a 12-h light/12-h dark cycle (lights on at 06:00) and with access to food and water ad libitum. Mice were acclimatized to the laboratory for at least 1 h before testing and were used only once throughout the experiments. The experiments were performed after approval of the protocol (PP00651) by the Institutional Ethics Committee and were carried out in accordance both with current guidelines for the care of laboratory animals and the ethical guidelines for investigations of experimental pain in conscious animals (Zimmermann, 1983) . The numbers of animals and intensities of noxious stimuli used were the minimum necessary to demonstrate consistent effects observed from diacerein treatment.
Intrathecal injections
Intrathecal injections were given to fully conscious mice using the method previously described by Hylden and Wilcox (1980) . Briefly, the animals were manually restrained, and a 30-gauge needle connected by a polyethylene tube to a 25 μl Hamilton syringe (Hamilton, Birmingham, UK) was inserted through the skin and between the vertebrae into the subdural space of the L5-L6 spinal segments. Intrathecal injections were given over a period of 5 s.
Intracerebroventricular injections
Intracerebroventricular (i.c.v.) administration was performed under ether anesthesia as previously described (Budni et al., 2007) . Briefly, a 0.4 mm external diameter hypodermic needle attached to a cannula, which was linked to a 25 μl Hamilton syringe was inserted perpendicularly through the skull and no more than 2 mm into the brain of the mouse. A volume of 5 μl was then administered in the left lateral ventricle. The injection was given over 30 s and the needle remained in place for another 30 s in order to avoid the reflux of the substances injected. The injection site was 1 mm to left from the mid-point on a line drawn through to the anterior base of the ears.
Abdominal constriction response caused by intraperitoneal injection of acetic acid
The abdominal constrictions resulting from intraperitoneal (i.p.) injection of acetic acid (0.6%, 450 μl) consist of a contraction of the abdominal muscle together with a stretching of the hind limbs and were induced according to procedures described previously . The mice were individually placed into glass cylinders of 20 cm in diameter and the abdominal constrictions were counted cumulatively over a period of 20 min. Antinociceptive activity was expressed as the reduction in the number of abdominal constrictions, i.e. the difference between control animals (mice pre-treated with vehicle) and animals pre-treated with drugs. Mice were pre-treated with diacerein (5-200 mg/kg) or with vehicle (10 ml/kg) by i.p. or intra-gastric (i.g.) routes, 30 and 60 min before the irritant injection, respectively. In an attempt to evaluate the possible spinal or supra-spinal antinociceptive action of diacerein, animals were treated with diacerein (5-100 μg/site) or with vehicle (5 μl/site) by intrathecal (i.t.) or intracerebroventricular (i.c.v.) routes, 10 min prior to injection of acetic acid.
In another set of experiments, we also evaluated the effect of diacerein (100-1000 μg/cavity) co-injected with the irritant agent. In addition, we investigated the time course of the antinociceptive effect of diacerein given i.p. (25 mg/kg) or i.g. (50 mg/kg) 0.5, 1, 2, 4 and 6 h before acetic acid administration. Control mice received an equal volume of vehicle and were observed at the same time intervals.
Nociception induced by glutamatergic agonists and proinflammatory cytokines
Animals received an i.p. injection of diacerein (25 mg/kg) or vehicle (10 ml/kg) 30 min before i.t. injection of 5 μl of algogen. Injections were given to fully conscious mice using the method described by Hylden and Wilcox (1980) (see Section 2.2) with minor modifications. The nociceptive response was elicited by glutamate (175 nmol/site), AMPA (a selective agonist of AMPA-subtype of glutamatergic ionotropic receptors, 135 pmol/site), NMDA (450 pmol/site, a selective agonist of the N-methyl-D-aspartic acid [NMDA] glutamatergic ionotropic receptor), kainate (a selective agonist of kainate-subtype of glutamatergic ionotropic receptors, 110 pmol/site) or trans-ACPD (50 nmol/site, a selective agonist for metabotropic glutamate receptors, that is active at both group I (mGlu1, mGlu5) and group II (mGlu2, mGlu3) receptors) (Scheidt et al., 2002; Gadotti et al., 2006; Martins et al., 2011) ; IL-1β (1 pg/site) and TNF-α (0.1 pg/site) (Choi et al., 2003; Lapa et al., 2009) .
Moreover, to verify the link played by the NMDA receptor on behavioral nociception induced by pro-inflammatory cytokines, we assessed the effect of MK-801 (0.05 mg/kg) given i.p., 0.5 h before test, on TNF-α (1 pmol/site)-and IL-1β (1 pmol/site)-induced nociception to the mice. Test duration was 15 min for trans-ACPD and each of the cytokines, 1 min for AMPA, 5 min for NMDA, 4 min for kainate and 3 min for glutamate. Nociceptive behaviors after i.t. delivery were defined as a single head movement directed at the flanks or hind limbs, resulting in contact of the animal's snout with the target organ. The amount of time (seconds) animals spent licking/biting their hind paws, tail or abdomen was determined with a chronometer and considered as nociceptive response (Scheidt et al., 2002; Gadotti et al., 2006; Martins et al., 2011 ).
Reagents
The following substances were used: diacerein (Trb Pharma, São Paulo, Brazil), acetic acid, Tween 80 and morphine hydrochloride (Merck, A.G., Darmstadt, Germany), L-glutamic acid hydrochloride (Sigma Chemical Co, St. Louis, USA). Kainic acid (kainate), (±)-1-Aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartic acid (NMDA) and MK-801 (Tocris, Cookson Inc., Ellisville, USA), tumor necrosis factor alpha (TNF-α), Interleukin-1β (IL-1β) (R&D Systems, Minneapolis, USA). All the drugs were dissolved in isotonic saline solution (0.9% NaCl, pH=5.5) with the exception of diacerein, which was dissolved in saline plus Tween 80. The corresponding pH values for the diacerein solution were 5.4, 5.5, and 5.0 for the 20 mg/ml (200 mg/kg), 10 mg/ml (100 mg/kg), and 2.2 mg/ml (1000 μg/site) solutions, respectively. The final concentration of Tween 80 did not exceed 5% and did not cause any effect per se. Also, control groups for each route of delivery received isotonic saline with 5% of Tween 80. The choice of the doses of each drug was based on previous data from our laboratory (Quintão et al., 2005; Gadotti et al., 2006; Martins et al., 2011) .
Statistical analysis
The results are presented as mean ± S.E.M., except the ID 50 values (i.e., the dose of diacerein that reduce the nociceptive response by 50% relative to the control value), which are reported as geometric means accompanied by their respective 95% confidence limits. The ID 50 value was determined by nonlinear regression from individual experiments using GraphPad software (GraphPad software, San Diego, CA, USA). The statistical significance of differences between groups was detected by t-tests or two-way ANOVA followed by Tukey's test when appropriate. P-values less than 0.05 were considered significant.
Results
Effect of diacerein on acetic acid-induced abdominal constrictions
In order to verify if diacerein reduces nociceptive signaling under visceral pain conditions, we examined the response of mice treated with diacerein after acid acetic injection. The results depicted in Fig. 1A and B show that diacerein, given by i.p. (30 min earlier) or i.g. (60 min before) routes, produced dose-related inhibition of acetic acid-induced abdominal constrictions in mice, with mean ID 50 values (with their 95% confidence limits) of 20.6 (16.1-26.2) and 35.6 (30.4-41.7) mg/kg and inhibition of 86±5% and 76±3%, respectively. Hence, diacerein was 1.8 fold more potent to reduced nociception when delivered by i.p. route than when delivered through i.g. route. A time-course analysis of the antinociceptive effect of diacerein is show in Fig. 1C and D. Diacerein produced marked antinociception as early as 30 and 60 min after i.p. (25 mg/kg) or i.g. (50 mg/kg) administration, respectively. This action remained significant up to 4 h after both systemic treatments. Thus, the time point (30 or 60 min for i.p. or i.g. routes, respectively) of maximum effect of diacerein was chosen for all further studies with independent groups of animals.
Diacerein also inhibited significantly the visceral nociceptive response when administered i.c.v., i.t. or peripherally (co-injected). The calculated mean ID 50 values were 32.4 (26.6-39.5), 27.1 (18.8-39.1) and 252.2 (235.2-270.4) μg/site and the inhibitions were 72 ± 9, 67 ± 9 and 57 ± 4%, respectively (Fig. 2) .
Effect of diacerein on glutamatergic agonists-and pro-inflammatory cytokines-induced nociception
To directly investigate the role of spinal glutamate receptors and pro-inflammatory cytokines in the antinociceptive action of diacerein, we compared the nociceptive behavior of mice treated with diacerein after a single intrathecal injection of glutamatergic agonist or pro-inflammatory cytokines. As shown in Fig. 3 , glutamate (175 nmol/ site, i.t.), AMPA (135 pmol/site, i.t.), NMDA (450 pmol/site, i.t.), trans-ACPD (50 nmol/site, i.t.), kainate (110 pmol/site, i.t.), TNF-α (0.1 pmol/site, i.t.) and IL-1β (1 pmol/site, i.t.) administration significantly induced nociception in mice (Fig. 3) . Diacerein (25 mg/kg, i.p.) inhibited the nociceptive behavior (licking/biting) responses induced by glutamate, NMDA, kainate and trans-ACPD with respectively inhibitions of 53±8, 61±13, 43±15 and 43±10%. In contrast, at the same dose, diacerein had no effect against AMPA-induced nociception (Fig. 3) . This possibly indicates that diacerein could act negatively modulating the activity of both ionotropic and metabotropic receptors. Furthermore, administration of diacerein (5-25 mg/kg, i.p.) produced significantly and dose-dependent attenuation of nociceptive responses induced by TNF-α and IL-1β. The mean ID 50 values from these results were 4.7 (3.2-7.0) and 10.8 (9.8-11.7) mg/kg and the observed inhibitions were 100 and 93±5%, respectively (Fig. 4) . injection of TNF-α and IL-1β with inhibitions of 92 ± 7 and 77 ± 9%, respectively.
Effect of MK-801 on pro-inflammatory cytokine-induced nociception
Discussion
This work demonstrates that diacerein elicits significant, dosedependent and long-lasting antinociception in acute nociception in mice. Several studies demonstrate that diacerein is an effective and well-tolerated agent for the treatment of osteoarthritis (Tamura et al., 1999 (Tamura et al., , 2001 and that rhein, an active metabolite of diacerein, inhibits certain pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α), besides controls the production of many pro-inflammatory mediators associated to painful pathophysiological conditions, such as rheumatoid arthritis and osteoarthritis (Martel-Pelletier, 1998; Pelletier et al., 2000; Pietrangelo et al., 1998; Tamura et al., 1999 Tamura et al., , 2001 Yaron et al., 1999) . Our group has shown that diacerein is able to inhibit in mice neuropathic pain induced by partial sciatic nerve ligation and inflammatory chronic pain induced by Complete Freund's Adjuvant (CFA) at a dose that do not seem to be directly associated with nonspecific sedative or muscle-relaxant actions because it did not affect the performance of mice on the rota-rod apparatus or their locomotor activity in the open-field test (Quintão et al., 2005) .
Our results show that diacerein administered systemically (i.p. or i.g. routes), supra-spinally (i.c.v.), spinally (i.t.) or peripherally (co-injected in association with the irritant agent) produced significant inhibition of nociception caused by intraperitoneal injection of acetic acid, demonstrating that diacerein produces antinociception in different sites of action (peripheral, spinal and supra-spinal). Acetic acid-induced writhing in mice is described as a typical model for visceral inflammatory nociception that has long been used as a screening tool for the assessment of analgesic or anti-inflammatory properties of new agents (Tjosen and Hole, 1997) . At the cellular level, protons depolarize sensory neurons by directly activating a non-selective cationic channel localized on cutaneous, visceral and other types of nocisponsive peripheral afferent C-fibers (Reeh and Kress, 2001; Julius and Basbaum, 2001) . It has been suggested that acetic acid acts by releasing endogenous inflammatory mediators of the nociceptive neurons (Collier et al., 1968) , such as bradykinin, prostaglandins and pro-inflammatory cytokines, when injected intraperitoneally (Ribeiro et al., 2000) . The main cytokines involved in nociception induced by acetic acid are TNF-α, IL-1β and interleukin 8, and they are released from resident peritoneal macrophages and mast cells (Ribeiro et al., 2000) . The concentration of glutamate and aspartate in the cerebrospinal fluid was increased after the injection of acetic acid (Fields et al., 1991; Zhu et al., 2004) . Furthermore, this test is sensitive to non-steroidal anti-inflammatory drugs (NSAIDs), narcotics and other centrally acting drugs (Collier et al., 1968) .
We also observed that diacerein effectively inhibited nociceptive responses induced by intrathecal injection of glutamate, thus raising the possibility that diacerein elicits antinociceptive activity by inhibiting glutamatergic transmission in the spinal cord. Moreover, selective agonists of each type of ionotropic and metabotropic glutamatergic receptors were used to investigate whether this action was receptor-specific. The results showed that diacerein inhibited the nociceptive response induced by NMDA, kainate and trans-ACPD, but not by AMPA. It is well established that glutamate is the most important neurotransmitter controlling the excitation of neurons within the dorsal horn of the spinal cord as a result of impulses arriving from primary afferent fibers. Furthermore, it has been demonstrated that activation of the NMDA receptor promotes induction of immediate early genes and further production of nociceptive and/or inflammatory mediators, such as prostaglandins (PG) and nitric oxide (NO) and pro-inflammatory cytokines (Hill, 2001) . Thus, part of the antinociceptive effect mediated by diacerein might be due to a direct effect on pro-inflammatory cytokines released after glutamate agonist injection. Of note, our group recently demonstrated that the NMDA blocker MK-801 also inhibited nociception induced by i.t. injection of glutamate, NMDA and trans-ACPD (Gadotti et al., 2006) .
Our results have shown that treatment of mice with diacerein was able to inhibit the nociceptive behavior induced by i.t. injection of the pro-inflammatory cytokines IL-1β and TNF-α. Pro-inflammatory cytokines released by peripheral injury mediate hyperalgesia and are involved in the sensitization of nociceptive fibers peripherally and centrally (Skott, 2003) . Their primary contribution to hypersensitivity results from potentiation of the inflammatory response and increased production of proalgesic agents such as prostaglandins, nerve growth factor (NGF) and bradykinin (Basbaum et al., 2009) . It is well known that TNF-α and IL-1β released from astrocytes enhance neuronal excitability and synaptic strength through the enhancement of the NMDA and AMPA subtype of glutamatergic receptors and also enhance the number of those receptors in the neuronal membrane (Stellwagen and Malenka, 2006) . Moreover, IL-1β enhances Ca 2+ influx through the NMDA receptor in the spinal cord contributing to nociceptive transmission (Viviani et al., 2003) . Recently, Zhang et al. (2008) showed that IL-1β phosphorylates the NR-1 subunit of the NMDA receptor leading to its activation. On the other hand, glutamate is able to activate glial cells leading to the subsequent release of pro-inflammatory cytokines, such as TNF-α and IL-1β (see review by Wieseler-Frank et al., 2004) . Here, we also show that MK-801 is able to reduce nociceptive response induced by i.t. injection of TNF-α and IL-1β. This result may be linked to the fact that pro-inflammatory cytokines, such as TNF-α and IL-1β, induce glutamate and SP release from nerve terminals in the spinal cord, which then contribute to nociceptive transmission (Basbaum et al., 2009 ). Our results show that diacerein produces antinociception against acetic acid-induced visceral as well as glutamatergic agonists and pro-inflammatory cytokines-induced somatic pain. Thus, diacerein could affect pain either by preventing the release of glutamate from primary afferents induced by pro-inflammatory cytokines and/or by inhibiting the activation of projection neurons by glutamate, through the inhibition of NMDA, kainate and metabotropic receptors, which contribute to the production and/or release of those pro-inflammatory cytokines such TNF-α and IL-1β in the spinal cord. However, additional studies will be required to confirm these hypotheses.
Conclusions
The findings of the present work provide evidence that diacerein exerts a rapid onset, relatively long-lasting and pronounced systemic, spinal, supra-spinal and locally antinociceptive action against acetic acid-induced visceral nociception in mice. In addition, a mechanism related to the inhibition of glutamate receptor activity and the inhibition of the activity of pro-inflammatory mediators seems to contribute to the analgesic properties of diacerein.
